BioSpace News Archive

Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has received FDA clearance to enter phase 1 study in patients with breast, melanoma, sarcoma and head and neck cancers.

Emergency departments and poison control centers are seeing a spike in patients who are suffering from the consequences of using unproven “treatments” for COVID-19, such as ivermectin—a medication often used for treating parasites in livestock.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference

10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares, each of which represents one ordinary share of Ascendis.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021.

Nevro Corp., a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, announced that Sri Kosaraju has been appointed as a member of the Board of Directors, effective August 31, 2021.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in August 2021.

Health Canada has received concerning reports of the use of veterinary ivermectin to prevent or treat COVID-19.